Logo image of SLXN

SILEXION THERAPEUTICS CORP (SLXN) Stock Fundamental Analysis

NASDAQ:SLXN - Nasdaq - KYG1281K1224 - Common Stock - Currency: USD

0.8478  +0.01 (+0.69%)

Fundamental Rating

1

Taking everything into account, SLXN scores 1 out of 10 in our fundamental rating. SLXN was compared to 556 industry peers in the Biotechnology industry. Both the profitability and financial health of SLXN have multiple concerns. SLXN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SLXN has reported negative net income.
SLXN had a negative operating cash flow in the past year.
In the past 5 years SLXN reported 4 times negative net income.
SLXN had negative operating cash flow in 4 of the past 5 years.
SLXN Yearly Net Income VS EBIT VS OCF VS FCFSLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -186.00%, SLXN is not doing good in the industry: 87.59% of the companies in the same industry are doing better.
The Return On Equity of SLXN (-597.55%) is worse than 79.50% of its industry peers.
Industry RankSector Rank
ROA -186%
ROE -597.55%
ROIC N/A
ROA(3y)-224.56%
ROA(5y)-174.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLXN Yearly ROA, ROE, ROICSLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

SLXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLXN Yearly Profit, Operating, Gross MarginsSLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for SLXN has been increased compared to 1 year ago.
SLXN has a worse debt/assets ratio than last year.
SLXN Yearly Shares OutstandingSLXN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
SLXN Yearly Total Debt VS Total AssetsSLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SLXN has an Altman-Z score of -10.72. This is a bad value and indicates that SLXN is not financially healthy and even has some risk of bankruptcy.
SLXN's Altman-Z score of -10.72 is on the low side compared to the rest of the industry. SLXN is outperformed by 75.18% of its industry peers.
SLXN has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
SLXN has a Debt to Equity ratio of 1.16. This is in the lower half of the industry: SLXN underperforms 78.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Altman-Z -10.72
ROIC/WACCN/A
WACCN/A
SLXN Yearly LT Debt VS Equity VS FCFSLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 3.22 indicates that SLXN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.22, SLXN is doing worse than 62.77% of the companies in the same industry.
SLXN has a Quick Ratio of 3.22. This indicates that SLXN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.22, SLXN is doing worse than 60.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 3.22
SLXN Yearly Current Assets VS Current LiabilitesSLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

SLXN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -901.14%.
EPS 1Y (TTM)-901.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.77% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.5%
EPS Next 2Y37.26%
EPS Next 3Y22.77%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLXN Yearly EPS VS EstimatesSLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SLXN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLXN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLXN Price Earnings VS Forward Price EarningsSLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLXN Per share dataSLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as SLXN's earnings are expected to grow with 22.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.26%
EPS Next 3Y22.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILEXION THERAPEUTICS CORP

NASDAQ:SLXN (7/25/2025, 1:44:38 PM)

0.8478

+0.01 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners9.1%
Inst Owner ChangeN/A
Ins Owners0.56%
Ins Owner Change0%
Market Cap7.37M
Analysts82.86
Price Target5.1 (501.56%)
Short Float %4.46%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-996.35%
Min EPS beat(2)-1976.83%
Max EPS beat(2)-15.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.85
P/tB 2.85
EV/EBITDA N/A
EPS(TTM)-11.01
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186%
ROE -597.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224.56%
ROA(5y)-174.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 3.22
Altman-Z -10.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-901.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.04%
EPS Next Y91.5%
EPS Next 2Y37.26%
EPS Next 3Y22.77%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1131.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-812.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-810.29%
OCF growth 3YN/A
OCF growth 5YN/A